文献速递眼底病与葡萄膜炎

二甲双胍与年龄相关性黄斑变性发生风险的关联

Association of Metformin With the Development of Age-Related Macular Degeneration.
PubMed 文献 · JAMA Ophthalmol · 2023-01-01

本研究为糖尿病预防计划结局研究的横断面随访,纳入1592例在试验后16年(2017-2019年)接受视网膜成像的参与者,比较生活方式、二甲双胍和安慰剂三组间年龄相关性黄斑变性(AMD)的患病率。结果显示三组AMD患病率无显著差异,二甲双胍使用时长与AMD也无关联,吸烟史与AMD风险升高相关(OR 1.30,95%CI 1.05-1.61,P=0.02)。

要点

  • 二甲双胍组AMD患病率30.2%,与安慰剂组30.7%和生活方式组29.6%相比无显著差异。
  • 二甲双胍平均使用时长在有和无AMD者中相似(8.0 vs 8.5年,P=0.69)。
  • 吸烟史与AMD风险升高相关(OR 1.30,95%CI 1.05-1.61,P=0.02)。

核心结论

  • 数据提示,为预防糖尿病而启动的二甲双胍或生活方式干预均与任何AMD的风险无关,AMD严重程度的结果相似。
  • 二甲双胍使用时长也与AMD无关。
  • 本分析未涉及二甲双胍与AMD发病率或进展的关联。

研究设计与样本

  • 糖尿病预防计划结局研究是大型多中心随机临床试验糖尿病预防计划(1996-2001)的横断面随访阶段。
  • 纳入在试验后16年随访访视(2017-2019)时接受视网膜成像的参与者,分析于2019年10月至2022年5月进行。
  • 参与者被随机分配至3个干预组:生活方式组、二甲双胍组和安慰剂组。

主要发现

  • 1592例参与者中,生活方式组514例(32.3%),二甲双胍组549例(34.5%),安慰剂组529例(33.2%)。
  • 479例(30.1%)发现AMD,其中早期AMD 229例(14.4%),中期AMD 218例(13.7%),晚期AMD 32例(2.0%)。
  • 三组AMD存在率无显著差异:生活方式组152例(29.6%),二甲双胍组165例(30.2%),安慰剂组162例(30.7%)。
  • 三组间早期、中期和晚期AMD的分布也无差异。
  • 有和无AMD者的二甲双胍平均使用时长相似(平均[SD],8.0[9.3] vs 8.5[9.3]年;P=0.69)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本分析未涉及二甲双胍与AMD发病率或进展的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Age-related macular degeneration (AMD) is a leading cause of blindness with no treatment available for early stages. Retrospective studies have shown an association between metformin and reduced risk of AMD. OBJECTIVE: To investigate the association between metformin use and age-related macular degeneration (AMD). DESIGN, SETTING, AND PARTICIPANTS: The Diabetes Prevention Program Outcomes Study is a cross-sectional follow-up phase of a large multicenter randomized clinical trial, Diabetes Prevention Program (1996-2001), to investigate the association of treatment with metformin or an intensive lifestyle modification vs placebo with preventing the onset of type 2 diabetes in a population at high risk for developing diabetes. Participants with retinal imaging at a follow-up visit 16 years posttrial (2017-2019) were included. Analysis took place between October 2019 and May 2022. INTERVENTIONS: Participants were randomly distributed between 3 interventional arms: lifestyle, metformin, and placebo. MAIN OUTCOMES AND MEASURES: Prevalence of AMD in the treatment arms. RESULTS: Of 1592 participants, 514 (32.3%) were in the lifestyle arm, 549 (34.5%) were in the metformin arm, and 529 (33.2%) were in the placebo arm. All 3 arms were balanced for baseline characteristics including age (mean [SD] age at randomization, 49 [9] years), sex (1128 [71%] male), race and ethnicity (784 [49%] White), smoking habits, body mass index, and education level. AMD was identified in 479 participants (30.1%); 229 (14.4%) had early AMD, 218 (13.7%) had intermediate AMD, and 32 (2.0%) had advanced AMD. There was no significant difference in the presence of AMD between the 3 groups: 152 (29.6%) in the lifestyle arm, 165 (30.2%) in the metformin arm, and 162 (30.7%) in the placebo arm. There was also no difference in the distribution of early, intermediate, and advanced AMD between the intervention groups. Mean duration of metformin use was similar for those with and without AMD (mean [SD], 8.0 [9.3] vs 8.5 [9.3] years; P = .69). In the multivariate models, history of smoking was associated with increased risks of AMD (odds ratio, 1.30; 95% CI, 1.05-1.61; P = .02). CONCLUSIONS AND RELEVANCE: These data suggest neither metformin nor lifestyle changes initiated for diabetes prevention were associated with the risk of any AMD, with similar results for AMD severity. Duration of metformin use was also not associated with AMD. This analysis does not address the association of metformin with incidence or progression of AMD.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Domalpally A, Whittier SA, Pan Q, et al. Association of Metformin With the Development of Age-Related Macular Degeneration. JAMA Ophthalmol. 2023. PMID: 36547967. doi:10.1001/jamaophthalmol.2022.5567

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。